Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Kristina Iribarren; Norma Bloy; Aitziber Buqué; Isabelle Cremer; Alexander Eggermont; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Špíšek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi

doi:10.1080/2162402X.2015.1088631

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Kristina Iribarren, Norma Bloy, Aitziber Buqué, Isabelle Cremer, Alexander Eggermont, Wolf Hervé Fridman, Jitka Fucikova, Jérôme Galon, Radek Špíšek, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi

Research output: Contribution to journal › Review article › peer-review

107 Citations (Scopus)

Abstract

ABSTRACT: Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various chemotherapeutics and targeted anticancer agents, at least in rodent tumor models. So far, only three TLR agonists have been approved by regulatory agencies for use in cancer patients. Moreover, over the past decade, the interest of scientists and clinicians in these immunostimulatory agents has been fluctuating. Here, we summarize recent advances in the preclinical and clinical development of TLR agonists for cancer therapy.

Original language	English
Journal	OncoImmunology
Volume	5
Issue number	3
DOIs	https://doi.org/10.1080/2162402X.2015.1088631
Publication status	Published - 3 Mar 2016
Externally published	Yes

Keywords

Ampligen™
bacillus Calmette-Guérin
G100
Hiltonol™
imiquimod
motolimod

Access to Document

10.1080/2162402X.2015.1088631

Cite this

@article{eb6cc60a1eaa4b1caf9b96cf08c92a8e,

title = "Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy",

abstract = "ABSTRACT: Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various chemotherapeutics and targeted anticancer agents, at least in rodent tumor models. So far, only three TLR agonists have been approved by regulatory agencies for use in cancer patients. Moreover, over the past decade, the interest of scientists and clinicians in these immunostimulatory agents has been fluctuating. Here, we summarize recent advances in the preclinical and clinical development of TLR agonists for cancer therapy.",

keywords = "Ampligen{\texttrademark}, bacillus Calmette-Gu{\'e}rin, G100, Hiltonol{\texttrademark}, imiquimod, motolimod",

author = "Kristina Iribarren and Norma Bloy and Aitziber Buqu{\'e} and Isabelle Cremer and Alexander Eggermont and Fridman, {Wolf Herv{\'e}} and Jitka Fucikova and J{\'e}r{\^o}me Galon and Radek {\v S}p{\'i}{\v s}ek and Laurence Zitvogel and Guido Kroemer and Lorenzo Galluzzi",

note = "Publisher Copyright: {\textcopyright} 2016, {\textcopyright} Taylor & Francis Group, LLC.",

year = "2016",

month = mar,

day = "3",

doi = "10.1080/2162402X.2015.1088631",

language = "English",

volume = "5",

journal = "OncoImmunology",

issn = "2162-4011",

publisher = "Landes Bioscience",

number = "3",

}

TY - JOUR

T1 - Trial Watch

T2 - Immunostimulation with Toll-like receptor agonists in cancer therapy

AU - Iribarren, Kristina

AU - Bloy, Norma

AU - Buqué, Aitziber

AU - Cremer, Isabelle

AU - Eggermont, Alexander

AU - Fridman, Wolf Hervé

AU - Fucikova, Jitka

AU - Galon, Jérôme

AU - Špíšek, Radek

AU - Zitvogel, Laurence

AU - Kroemer, Guido

AU - Galluzzi, Lorenzo

PY - 2016/3/3

Y1 - 2016/3/3

N2 - ABSTRACT: Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various chemotherapeutics and targeted anticancer agents, at least in rodent tumor models. So far, only three TLR agonists have been approved by regulatory agencies for use in cancer patients. Moreover, over the past decade, the interest of scientists and clinicians in these immunostimulatory agents has been fluctuating. Here, we summarize recent advances in the preclinical and clinical development of TLR agonists for cancer therapy.

AB - ABSTRACT: Accumulating preclinical evidence indicates that Toll-like receptor (TLR) agonists efficiently boost tumor-targeting immune responses (re)initiated by most, if not all, paradigms of anticancer immunotherapy. Moreover, TLR agonists have been successfully employed to ameliorate the efficacy of various chemotherapeutics and targeted anticancer agents, at least in rodent tumor models. So far, only three TLR agonists have been approved by regulatory agencies for use in cancer patients. Moreover, over the past decade, the interest of scientists and clinicians in these immunostimulatory agents has been fluctuating. Here, we summarize recent advances in the preclinical and clinical development of TLR agonists for cancer therapy.

KW - Ampligen™

KW - bacillus Calmette-Guérin

KW - G100

KW - Hiltonol™

KW - imiquimod

KW - motolimod

UR - http://www.scopus.com/inward/record.url?scp=84961671432&partnerID=8YFLogxK

U2 - 10.1080/2162402X.2015.1088631

DO - 10.1080/2162402X.2015.1088631

M3 - Review article

AN - SCOPUS:84961671432

SN - 2162-4011

VL - 5

JO - OncoImmunology

JF - OncoImmunology

IS - 3

ER -

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

Abstract

Keywords

Access to Document

Fingerprint

Cite this